Rajeev Rajani, MD
Adolescent Medicine · Naples, FLNPI 1316038698
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.0% of the total across 288 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 32 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,350 and has fallen 72.2% since, to $376 in 2025. Among adolescent medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 288 payments — averaging $22.50 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Amgen$1K
- GSK$766
- Novo Nordisk$521
- Johnson & Johnson$386
- Medtronic$314
- plus $2K from 26 others
What the payments were for
- Food & beverage$6,35098%
- Education$1312%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 57 | $1,260 |
| Amgen(2 entities) | 44 | $1,013 |
| GSK | 45 | $766 |
| Novo Nordisk | 34 | $521 |
| Johnson & Johnson | 15 | $386 |
| Medtronic | 2 | $314 |
| Boehringer Ingelheim | 9 | $308 |
| Pfizer | 11 | $197 |
| Smith+Nephew | 4 | $173 |
| Amarin Pharma, Inc. | 6 | $162 |
| Novartis | 8 | $156 |
| Astellas Pharma US Inc | 4 | $135 |
| Lilly USA, LLC | 7 | $120 |
| Bayer | 6 | $118 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $115 |
| Esperion Therapeutics, Inc. | 6 | $99 |
| Boston Scientific | 2 | $95 |
| Merck | 5 | $95 |
| Exact Sciences | 3 | $80 |
| Organogenesis Inc. | 1 | $46 |
| Axonics, Inc. | 2 | $45 |
| Biogen | 2 | $44 |
| Sunovion Pharmaceuticals Inc. | 2 | $34 |
| Kowa Pharmaceuticals America, Inc. | 2 | $33 |
| Radius Health, Inc. | 2 | $31 |
| Abbott | 2 | $28 |
| Idorsia Pharmaceuticals US Inc | 1 | $23 |
| Eisai Inc. | 1 | $20 |
| Genentech USA, Inc. | 1 | $20 |
| AbbVie | 1 | $18 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,481 in reported general payments places this provider in the 95th percentile of 113 adolescent medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 142 | $167,897 |
| JardianceEmpagliflozin | 107 | $155,271 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 11 | $117,114 |
| OzempicSemaglutide | 73 | $80,543 |
| XareltoRivaroxaban | 62 | $75,608 |
| TrulicityDulaglutide | 58 | $71,018 |
| JanuviaSitagliptin Phosphate | 51 | $70,783 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 34 | $43,031 |
| MounjaroTirzepatide | 30 | $30,987 |
| FarxigaDapagliflozin Propanediol | 21 | $22,179 |
| Breo ElliptaFluticasone/Vilanterol | 40 | $19,823 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 30 | $18,264 |
| Repatha SureclickEvolocumab | 16 | $16,461 |
| Tresiba Flextouch U-100Insulin Degludec | 15 | $12,129 |
| Rosuvastatin Calcium | 663 | $10,443 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $197 | $167,897142 claims |
| Boehringer IngelheimJardiance | $308 | $155,271107 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid | $115 | $117,11411 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $120 | $102,00588 claims |
| Novo NordiskOzempic | $521 | $80,54373 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Shingrix, Anoro Ellipta | $766 | $79,559131 claims |
| Johnson & JohnsonXarelto | $386 | $75,60862 claims |
| MerckJanuvia | $95 | $70,78351 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $1,260 | $40,44251 claims |
| AbbVieSynthroid | $18 | $6,476105 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 113 adolescent medicine providers in Florida.
Other adolescent medicine in Naples
- Dulce DudleyNaples$599
- Pedro NamLoxaharchee$9K
- Lonna GordonOrlando$6K
- Meera BeharryFort Pierce$5K
- Nasin David RiveraOrlando$4K
- Heather Elizondo VegaWinter Garden$3K
- Adriana CastroMiami$3K
- Richard MillerNew Port Richey$3K
- Quy VinhMiami$3K
- Laritssa CobianOrlando$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.